find a clinic

Prism For PTSD

What is Prism for PTSD?

Prism for PTSD is an evidence-based, prescription therapy, FDA-cleared to treat PTSD.  During Prism treatment, a computer simulation and EEG headset create an environment where patients engage in a non-trauma-based experience to help them learn to control their PTSD symptoms.

Prism is the first PTSD treatment based on a digital brain-mechanism-specific biomarker associated with mental health disorders.

Prism Regimen

  • 15 sessions, over 8 weeks or as determined by healthcare provider.
  • Booster sessions as needed
  • Each session lasts about 45 minutes.

Prism Regimen

  • 15 sessions, over 8 weeks or as determined by healthcare provider.
  • Booster sessions as needed
  • Each session lasts about 45 minutes.

Proven Clinical Outcomes

Clinical studies have demonstrated durable improvement in PTSD symptoms with a high safety profile.

Operational Simplicity

With installation and training taking four hours, team can be trained in the morning and treating patients the same afternoon.

Reduced Costs

Prism can be operated by a non-MD healthcare professional, such as an NP,  social worker or technician. 

Engaged Patient Experience

Personalized, non-trauma based treatment that helps patients gain a sense of control over their PTSD symptoms, and their lives.

Clinical Results

The Prism for PTSD multi-center clinical study demonstrated the following results. 3 months after the 15-session regimen (5 months from baseline):

  • 67% of patients overall demonstrated clinically significant symptom improvement as measured by CAPS-5.
  • Significant improvement in sleep, as measured by PHQ-9 and CAPS-5.
  • 32% of patients experienced remission.
  • 90% patient compliance.
  • Mild side effects, such as fatigue and headache, resolved after treatment with no further intervention. 
  • We utilize the first PTSD treatment based on a digital biomarker of brain activity associated with mental health disorders. The proprietary EEG-fMRI-Pattern (EFP) digital biomarker was developed by applying advanced statistical models to register amygdala fMRI data to EEG. This has never been done before.
  • Prism for PTSD, uses the amygdala-based biomarker because research has shown that PTSD is associated with hyperactivity of the amygdala, the center of our fight-flight response.
  • Prism for PTSD gathers years of neuroscience research and places it into the hands of mental healthcare providers. Combining an innovative software with an affordable FDA-approved EEG headset for neurofeedback​The National Institute of Mental Health (NIMH), Division of Translational Research convened a virtual workshop where researchers and FDA officials reviewed the state of the science for neurofeedback (NF) intervention for mental disorders. The program highlighted Prof. Talma Hendler, MD, PhD presenting how she and her team developed the innovative amygdala-based EFP biomarker in the research lab, and insights on the journey to FDA clearance and the use of Prism for PTSD for patient care in clinics today.

 

Copyright @ 2025 ALTMED